News

Rate of BRCA testing up among young women with breast cancer


 

FROM JAMA ONCOLOGY

References

The rate at which young women diagnosed with breast cancer are undergoing genetic testing for BRCA1 and BRCA2 mutations has increased, investigators report online in JAMA Oncology.

In a study of 897 women aged 40 years and younger diagnosed with breast cancer at any one of 11 academic or community medical centers, 780 (87%) reported undergoing BRCA testing within the first year after diagnosis, reported Dr. Ann H. Partridge of the Dana-Farber Cancer Institute, Boston, and her associates (JAMA Onc. 2016 Feb 11. doi: 10.1001/jamaoncol.2015.5941).

Dr. Ann H. Partridge

Dr. Ann H. Partridge

Among the 780 women who had BRCA testing, 59 (7.6%) reported a BRCA1 mutation, 35 (4.5%) reported a BRCA2 mutation, and 35 (4.6%) reported an indeterminate result or variant of unknown clinical significance, the investigators said.

The frequency of testing increased over time. Of 39 women diagnosed with breast cancer in 2006, 30 (76.9%) elected to have testing, but by 2013, 123 (95.3%) of 129 women diagnosed with breast cancer reported BRCA testing.

The investigators attribute the increasing frequency of BRCA testing to the fact that most women in the group were insured, educated, and treated at cancer centers where comprehensive genetic counseling and testing services were widely available, but they also acknowledged the possibility that media attention to genetic breast cancer (in other words, the Angelina Jolie effect) may have motivated more women to bring up the issue of genetic risk with their physician or genetic counselor.

The study can be found online here.

lnikolaides@frontlinemedcom.com

On Twitter @NikolaidesLaura

Recommended Reading

A Perfect Storm: Tumor biology and genomics
MDedge Hematology and Oncology
SABCS: Longer overnight fasting may reduce breast cancer recurrence risk
MDedge Hematology and Oncology
RCTs vs. observational studies: mortality ‘strikingly’ different following RT
MDedge Hematology and Oncology
Significant risk of relapse remains for ER-positive breast cancer patients beyond 10 years
MDedge Hematology and Oncology
David Bowie’s death inspires blog on palliative care
MDedge Hematology and Oncology
A call for definitive trial of statins in breast cancer
MDedge Hematology and Oncology
Acupressure improves persistent fatigue in breast cancer survivors
MDedge Hematology and Oncology
Smoking after breast cancer diagnosis a risk factor in cancer death
MDedge Hematology and Oncology
Patient prognostic score may lessen DCIS overtreatment
MDedge Hematology and Oncology
Epoetin alfa missed its safety endpoint in metastatic breast cancer
MDedge Hematology and Oncology